SCHEMBL1764664

SCHEMBL1764664

COc1ccc(-c2cc(=O)c3c(O)c(OC)c(O)c(OC)c3o2)cc1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.86
MAPT P10636 3/20 0.86
CYP3A4 P08684 3/20 0.86
MAPK1 P28482 2/20 0.86
USP2 O75604 1/20 0.86
LMNA P02545 1/20 0.86
ELANE P08246 1/20 0.86
KDM4E B2RXH2 2/20 0.73
MEN1 O00255 2/20 0.73
KMT2A Q03164 2/20 0.73
ABCB1 P08183 1/20 0.73
HPGD P15428 1/20 0.73
HSD17B10 Q99714 1/20 0.73
ABCG2 Q9UNQ0 1/20 0.73
POLB P06746 1/20 0.70
GAA P10253 1/20 0.70
RECQL P46063 1/20 0.70
L3MBTL1 Q9Y468 1/20 0.70
CYP1A1 P04798 1/20 0.70
CYP1A2 P05177 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
5-Demethylnobiletin SCHEMBL29606981 0.93 ALDH1A1 (1.00) ALDH1A1MAPTCYP3A4MAPK1USP2
5-Demethylnobiletin SCHEMBL1764120 0.93 ALDH1A1 (1.00) ALDH1A1MAPTCYP3A4MAPK1USP2
5-Demethylnobiletin SCHEMBL31237479 0.93 ALDH1A1 (1.00) ALDH1A1MAPTCYP3A4MAPK1USP2
SCHEMBL25225757 0.93 ALDH1A1 (0.82) ALDH1A1MAPTCYP3A4MAPK1USP2
Sudachitin SCHEMBL6361479 0.91 ALDH1A1 (0.84) ALDH1A1MAPTCYP3A4MAPK1USP2
Sudachitin SCHEMBL29435872 0.91 ALDH1A1 (0.84) ALDH1A1MAPTCYP3A4MAPK1USP2
SCHEMBL12469965 0.91 ALDH1A1 (0.72) ALDH1A1MAPTCYP3A4MAPK1USP2
SCHEMBL17963714 0.90 ALDH1A1 (0.91) ALDH1A1MAPTCYP3A4MAPK1USP2
SCHEMBL25263457 0.90 ALDH1A1 (0.86) ALDH1A1MAPTCYP3A4MAPK1USP2
SCHEMBL30683238 0.86 PPARG (0.85) ALDH1A1MAPTCYP3A4MAPK1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4698662-A2 REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES AskBio Inc. (US) 2026-02-25 EP claimed
WO-2024220449-A9 REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES AskBio Inc. (US) 2025-04-03 WO claimed
US-20250011393-A1 FLAVONOID-COLLAGEN CROSSLINKED ANTIOXIDANT HYDROGEL NORTH CAROLINA STATE UNIVERSITY 2025-01-09 US claimed
WO-2024220449-A2 REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) 2024-10-24 WO claimed
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US claimed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
WO-2022182523-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
CN-102018740-A Medicinal composition containing extracts of leaves of helianthus and application of the same PEIXUE LING 2011-04-20 CN claimed
JP-2009506057-A 2009-02-12 JP claimed
EP-1928480-A2 METHODS FOR MANAGING ADIPOCYTE FAT ACCUMULATION Wellgen, Inc. (US) 2008-06-11 EP claimed
EP-1883300-A2 COMPOSITIONS AND METHODS FOR OPTIMIZING EXERCISE RECOVERY Rutgers, The State University of New Jersey (US) 2008-02-06 EP claimed
US-20070275106-A1 Hydroxylated polymethoxyflavone compositions WELLGEN, INC. 2007-11-29 US claimed
US-20070088078-A1 Methods for managing adipocyte fat accumulation WELLGEN, INC. 2007-04-19 US claimed
US-7201928-B1 Extracts of orange peel for prevention and treatment of cancer RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2007-04-10 US claimed
WO-2007024982-A2 METHODS FOR MANAGING ADIPOCYTE FAT ACCUMULATION WELLGEN, INC. (US) 2007-03-01 WO claimed
US-20070042972-A1 Compositions and methods for optimizing exercise recovery RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2007-02-22 US claimed
WO-2006127996-A2 COMPOSITIONS AND METHODS FOR OPTIMIZING EXERCISE RECOVERY RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2006-11-30 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070042972-A1 Compositions and methods for optimizing exercise recovery GYS1, PYGM, PRDX5 ALDH1A1 3163/4885MAPT 4515/4885CYP3A4 144/4885
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB ALDH1A1 2722/4885MAPT 3926/4885CYP3A4 3571/4885
US-20070088078-A1 Methods for managing adipocyte fat accumulation FABP4, PLIN5, PLIN3 ALDH1A1 1272/4885MAPT 3872/4885CYP3A4 1574/4885
US-20070275106-A1 Hydroxylated polymethoxyflavone compositions PLIN5, FANCF, COXFA4 ALDH1A1 1794/4885MAPT 4329/4885CYP3A4 390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.